Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Patent
1997-05-09
1999-07-06
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
A61K 31195
Patent
active
059198230
ABSTRACT:
The present invention relates to a method of remitting or attenuating the symptoms of movement disorders which can be secondary to treatment of psychiatric disorders with antipsychotic drugs mainly neuroleptics, movement disorders that arise secondary to non-neuroleptic drugs in the treating of non-psychiatric disorders or primary neurological disorders. This treatment involves administering a meal enriched with large neutral amino acids or a dietary supplement of large neutral amino acids to patients suffering from these disorders.
REFERENCES:
patent: 4100293 (1978-07-01), Walser et al.
patent: 4129652 (1978-12-01), Fuxe
patent: 4138484 (1979-02-01), Fuxe
patent: 4209531 (1980-06-01), Berry
patent: 4252822 (1981-02-01), Berry
patent: 4320146 (1982-03-01), Walser
patent: 4438144 (1984-03-01), Blackburn
patent: 4687782 (1987-08-01), Brantman
patent: 4780475 (1988-10-01), Cerra et al.
patent: 4837219 (1989-06-01), Hutterer
patent: 5006559 (1991-04-01), Askanazi et al.
patent: 5017616 (1991-05-01), Askanazi
patent: 5026721 (1991-06-01), Dudrick et al.
patent: 5028622 (1991-07-01), Plaitakis
patent: 5256669 (1993-10-01), Askanazi et al.
patent: 5256697 (1993-10-01), Miller et al.
Branched-chain amino acids and amyotrophic lateral sclerosis: A treatment failure? Neurology 1993; 43:2466-2470.
A controlled trial of amino acid therapy in amyotropic lateral sclerosis: I. Clinical, functional, and maximum isometric torque data; Neurology 1996; 47:1220-1226.
Effect of branched-chain amino acids on glutamate metabolism . . . sclerosis; Journal of Neurological Sciences 1995; 129:40-43.
"Alzheimer's disease: neuropathological correlates of cognitive and motor disorders"; Acta Neurol Scand., 1987; 75:376-384.
"A SPECT Study of Parkinsonism in Alzheimer's Disease" The Journal of Neutropsychiatry and Clinical Neurosciences; 1995; 7:308-313.
"Alzheimer Disease: Clinical and Biological Heterogeneity"; Annals of Internal Medicine; 1988: 109:298-311.
"A Clinicopathologic Study of 100 Cases of Parkinson's Disease"; Arch Neurol; 1993; 50:140-148.
"Clinical subtypes of dementia of the Alzheimer type"; Neurology; 1985; 35:1544-1550.
"Action Myoclonus, Ramsay Hunt Syndrome, and Other Cerebellar Myoclonic Syndromes"; Advances in Neurology; 1986; 43:35-55.
"Cerebrospinal Fluid Neurochemistry in the Myoclonic Subtype of Alzheimer's Disease"; Ann Neurol; 1988; 24:647-650.
"Cumulative Risks of Developing Extrapyramidal Signs, Psychosis, or Myoclonus in the Course of Alzheimer's Disease"; Arch Neurol.; 1991; 48:1141-1143.
"Clinical and Positron Emission Tomographic Studies in the `Extrapyramidal Syndrome` of Dementia of the Alzheimer Type"; Arch Neurol.; 1990; 47:1318-1323.
"An Autopsy Case of Alzheimer Disease with Myoclonus and Periodic Spikes on EEG"; Jpn J Psychiatry Neurol; 1994; 48:615-621.
"Interrater Reliability of Extrapyramidal Signs in a Group Assessed for Dementia"; Arch Neurol.; 1991; 48:1147-1149.
"Heterogeneity in demential of the Alzheimer type: Evidence of subgroups"; Neurology; 1985; 35:453-461.
"The Absence of an Apolipoprotein . . . Aggressive Form of Alzheimer's Disease"; Ann Neurol; 1997; 41:615-620.
"Myoclonus in Alzheimer's disease"; J Neurol; 1987; 235:90-94.
Familial Alzheimer's Disease With Myuoclonus and `Spongy Change`; Arch Neurol; 1988: 45:1097-1100.
Extrapyramidal signs in Alzheimer's disease; Neurology; 1984; 34:11145-1116.
"Myoclonus in Alzheimer Disease"; Arch Neurol; 1976; 33:278-280.
"Myoclonus, Seizures, and Paratonia in Alzheimer Disease"; Alzheimer Disease and Associated Disorders; 1990 Raven Press, Ltd., New York; vol. 4, No. 4., pp. 217-225.
"Myoclonus in Down's Syndrome Associate With Alzheimer's Disease"; Arch Neurol; 1981; 38:453-454.
Neurologic Signs in Alzheimer's Disease Results of a Prospective Clinical and Neuropathologic Study; Arch Neurol.; 1992; 49:1038-1042.
"Pisa Syndrome in Alzheimer's Disease"; Biol Psychiatry; 1988; 23:209-214.
"The Neurologic Syndrome of Servere Alzheimer's Disease Relationship to Functional Decline"; Arch Neurol.; 1993; 50:1029-1039.
Relationship between primitive reflexes, extra-pyramidal sings, . . . in dementia of the Alzheimer type; Acta neurol. Scand; 1989; 79:38-46.
"Neuronal Loss in the Substantia Nigra in . . . Disease in Relation to Extrapyramidal Symptoms and Dementia"; Alzheimer's Disease and Related Disorders; 1989 Alan R. Liss, Inc.; pp. 325-332.
"Myoclonus in Alzheimer's Disease and Minipolymyoclonus"; Advances in Neurology; 1986; 43:399-405.
Psychopharmacol. Bull., vol. 25, No. 1, 1989, pp. 47-51.
J. Psychopharmacol, vol. 6, No. 2, 1992, pp. 278-280.
Int. J. Neurosciences, vol. 42, 1988, pp. 127-130.
Psychopharmacology, vol. 99, No. 3, 1989, pp. 299-303.
Bremer, H.J., et al, Disturbances of Amino Acid metabolism:Clinical Chemistry and Diagnosis, Baltimore: Urban & Schwarzenberg, 1981.
Bowers et al, J. Clin Psychopharmacol, vol. 7, No. 1, Feb. 1987 pp. 57-58.
Richardson, et al., Journal of Psychopharmacology, 7(2) (1993) pp. 219-220.
Richardson, et al., Biological Psychiatry, vol. 2, Proceedings fo the 5th World Congress of Biological Psychiatry, (Excerpta Medica), 1991, pp. 341-343.
2nd International Symposium on Serotonin from Cell Biology to Pharmacology and Therapeutics, Sep., 1992 Abstract Book, p. 4.
Joint Meeting of 4th International Trace Amines Conference and 5th International Amine Oxidase Workshop Aug., 1992.
Bowers, et al., J. Clinical Psychopharmacol., 7:57-58 (1987).
Fibiger, et al., TINS, pp. 462-464 (Dec. 1984).
Stegink, L.D., et al. Aspartame Physiology and Biochemistry, New York: Marcel Dekker, pp. 509-553 (1984)
Delgado, P.L., et al., "Serotonin function and the mechanism of antidepressant action. Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan,"Arch. Gen. Psychiatry, 1990, 47:411-418.
Sloviter, R.S., et al. "Serotonergic properties of b-phenylethylamine in rats," Neuropharmacology, 1980 19:1071-1074.
Dourish, CT, "Behavioral effects of acute and chronic b-phenylethylamine administration in the rat: evidence of the involvement of 5-hydroxytryptamine," Neuropharmacology, 1981, 20:1067-1072.
Hagenfeldt, L., et al. "Amino acids in plasma and CSF and monoamine metabolites in CSG: interrelationship in health subjects," J. Neurochem., 42(3):833-837, 1984.
Rao, J.L., et al. "Serum amino acids, central monoamines, and hormones in drug-naive, drug-free, and neuroleptic-treated schizophrenic patients and healthy subjects," Psychiatry Res.. 34:243-257, 1990.
Gardos, et al., "The Acute Effects of a Loading Dose of Phenylalanine in Unipolar Depressed Patients With and Without Tardive Dyskinesia," Neuropsychopharmacology, 1992, vol. 6, No. 4.
Lohr, et al., Schizophr. Bull., 14:291-296 (1988).
Cadet, et al., Ann. NY Acad. Sci. 570:176-185 (1989).
Lu, et al., Biol. Psychiatry, 25:717-724 (1989).
Pardridge, W.M., Nutrition and the Brain, vol. 7: 199-241, New York: Raven Press (1986).
Giovannini, M., et al., "Serotonin and noradrenaline concentrations and serotonin uptake in platelets from hyperphenylalaninemic patients," J. Inherited Metab. Dis. 1988, 11:285-290.
Bjerkenstedt, L., et al. "Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls," Br. J. Psychiatry, 1985, 147:276-282.
Tamminga, et al., Arch. Gen. Psychiatry, 36:595-598 (1979).
Thaker. et al., Arch. Gen. Psychiatry, 44:522-529 (1987).
Stahl, et al., Biol. Psychiatry, 20:888-893 (1985).
Andersson, et al., Mov. Disord., 4(1):37-46 (1989).
Thaker, et al., Biol. Psychiatry, 25:49-59 (1989).
Gunne, et al., Nature, 309:347-349 (1984).
Jus, K., et al. "Studies on the action of certain pharmacological agents on tardive dyskinesia and on rabbit syndrome," Int. J. Clin. Pharmacol. 1974, 9(2):138-145.
Lakke & Teelken, Neurogy, 26, 489-493 (1976).
Seeman, P., J. Clinical Psychopharmacol., 8 (4, supp):3S-9s (1988).
Jeste, et al., Br. J. Psychiatry, 144:177-180 (1984).
Wagner, et al., J. Clinical Psychopharmacol., 2:312-314 (1982).
Kaufman, et al., Biol. Psychiatry, 21:799-812 (1986).
Van Woert, et al., Monographs in Neural Sciences, 3, 71-80, (1976).
Avanzini, et
Criares Theodore J.
The Research Foundation For Mental Hygiene
LandOfFree
Treatment of secondary movement disorders using large neutral am does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of secondary movement disorders using large neutral am, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of secondary movement disorders using large neutral am will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-899429